- Home
- BRT vs PALI Comparison
BRT vs PALI Comparison
Compare BRT & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$14.12
HOLD
Current Price
$1.95
Company Overview
Basic Information| Metric | BRT | PALI |
|---|---|---|
| Founded | 1972 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 282.3M | 240.2M |
| IPO Year | 1994 | 2019 |
Fundamental Metrics
Financial Performance| Metric | BRT | PALI |
|---|---|---|
| Price | $14.12 | $1.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $19.75 | $13.00 |
| AVG Volume (30 Days) | 23.4K | ★ 2.8M |
| Earning Date | 06-24-2026 | 01-01-0001 |
| Dividend Yield | ★ 6.93% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $97,028,000.00 | $260,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.72 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 1.46 | ★ 1500.39 |
| 52 Week Low | $14.00 | $0.55 |
| 52 Week High | $18.50 | $2.64 |
Technical Indicators
Market Signals| Indicator | BRT | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 35.93 | 57.47 |
| Support Level | N/A | $1.58 |
| Resistance Level | $15.11 | $2.21 |
| Average True Range (ATR) | 0.32 | 0.13 |
| MACD | -0.06 | 0.03 |
| Stochastic Oscillator | 0.00 | 71.58 |
Price Performance
Historical Comparison BRT
PALI
About BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.